We performed a meta-analysis of 2 genome-wide association studies of
coronary artery disease comprising 1,515 cases with coronary artery disease and
5,019 controls, followed by de novo replication studies in
15,460 cases and 11,472 controls, all of Chinese Han descent. We successfully
identified four new loci for coronary artery disease reaching genome-wide
significance (P < 5 × 10−8),
which mapped in or near TTC32-WDR35, GUCY1A3,
C6orf10-BTNL2 and ATP2B1. We also
replicated four loci previously identified in European populations
(PHACTR1, TCF21, CDKN2A/B
and C12orf51). These findings provide new insights into
biological pathways for the susceptibility of coronary artery disease in Chinese
Han population.
The aim of the current study is to determine the impact of elevated lipoprotein(a) [Lp(a)] on cardiovascular events (CVEs) in stable coronary artery disease (CAD) patients with different glucose metabolism status. RESEARCH DESIGN AND METHODS In this multicenter study, we consecutively enrolled 5,143 patients from March 2011 to February 2015. Patients were categorized according to status of glucose metabolism (diabetes mellitus [DM], pre-diabetes mellitus [pre-DM], and normal glucose regulation [NGR]) levels and further classified into 12 groups by Lp(a) levels. CVE end points included nonfatal acute myocardial infarction (MI), stroke, and cardiovascular mortality. All subjects were followed up for the occurrence of the CVEs. RESULTS During a median of 6.1 years' follow-up, 435 (8.5%) CVEs occurred. No significant difference in occurrence of CVEs was observed between NGR and pre-DM groups (hazard ratio 1.131 [95% CI 0.822-1.556], P > 0.05). When status of glucose metabolism was incorporated in stratifying factors, 30 £ Lp(a) < 50 mg/dL and Lp(a) ‡50 mg/dL were associated with significantly higher risk of subsequent CVEs in pre-DM (2.181 [1.099-4.327] and 2.668 [1.383-5.415], respectively; all P < 0.05) and DM (3.088 [1.535-5.895] and 3.470 [1.801-6.686], all P < 0.05). Moreover, adding Lp(a) to the Cox model increased the C-statistic by 0.022 and 0.029 in pre-DM and DM, respectively, while the C-statistic was not statistically improved when Lp(a) was included for CVEs prediction in NGR. CONCLUSIONS Our findings, for the first time, indicated that elevated Lp(a) levels might affect the prognosis in patients with pre-DM with stable CAD, suggesting that Lp(a) may help further stratify stable CAD patients with mild impaired glucose metabolism. Lipoprotein(a) [Lp(a)] is an LDL-like particle consisting of a moiety of apolipoprotein(a) bounding covalently to apolipoprotein B-100 (1,2). Plasma Lp(a) induces proatherogenic effects via LDL moiety and prothrombotic effects by the plasminogen-like apolipoprotein(a) (3,4). Strong evidence in epidemiological, genetic, and prospective cohort studies verified that circulating Lp(a) levels were associated with the presence of cardiovascular disease (CVD) (5-7). In the Atherothrombosis
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.